title: What lessons can be learnt from withdrawal of mibefradil from the market?
authors.affiliation: Centre for Evidence-Based Pharmacotherapy, University of Nottingham, UK.
authors.forename: A L
authors.initials: AL
authors.lastname: Po
authors.forename: W Y
authors.initials: WY
authors.lastname: Zhang
mesh_terms: D000329:Advertising; D001562:Benzimidazoles / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D017277:Drug Approval; D004347:Drug Interactions; D005060:Europe; D006801:Humans; D020748:Mibefradil; D011358:Product Surveillance, Postmarketing; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*; D014481:United States
chemical_list: D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil